WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Insights
Type
People
Practices
Industries
From Date
To Date
Reset Search

Search Results

Client Highlights

7.15.26

Wilson Sonsini Advises InstaLILY AI on $60 Million Series B
On July 14, 2026, InstaLILY AI, creator of Lily, the world's first AI Forward Deployed Engineer, announced a $60 million Series B round led by Energize Capital. The round included participation from Insight Partners, which increased its investment, and new strategic investors including Home Depot Ventures and United Rentals. The Series B brings InstaLILY’s total raised to nearly $100 million, after a year in which the company’s revenue grew by a multiple of five. Wilson Sonsini Goodrich & Rosati advised InstaLILY on the transaction.

Lily goes into a business, learns how it works, builds what the work needs, and gets it running by finding revenue, pricing quotes, planning routes, and diagnosing equipment in the field. Unlike a traditional demo or pilot, it runs the business with people in control, and it goes live in days versus months. After launch, it keeps shipping and gets better the longer it runs. InstaLILY will use the Series B funding to help Lily learn faster, take on more of the work, expand into new industries, and grow the team. The company will also continue building the Small Data Center, the infrastructure that makes always-on intelligence possible inside a business, at a cost and energy profile enterprises can sustain.

The Wilson Sonsini team that advised InstaLILY on the transaction included Megan Baier, Sam Obenhaus, and Richard Fielkow.

For more information, please see the company’s news release and blog post.
Client Highlights

6.24.26

Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Client Highlights

3.24.26

Firm Advises Dimer Health on $13.5 Million Series A Financing
On March 23, 2026, Dimer Health, a clinician-led, AI-native transitional care medicine company, announced $13.5 million in Series A financing led by Team8 and Bill Ackman's Table Management, with participation from existing investors Silver Circle and TechAviv. The round brings the company's total funding to $20 million and will support national expansion of Dimer's dedicated post-discharge clinical service line, now operating across eight states. Wilson Sonsini Goodrich & Rosati advised Dimer on the transaction.
Client Highlights

3.13.26

Wilson Sonsini Advises Urgently on Acquisition by Agero
On March 13, 2026, Agero, a software-enabled driver safety services and technology company, announced that it has entered into an agreement to acquire Urgent.ly (Urgently), a digital software platform that provides roadside and mobility assistance, for a cash price of $5.50 per share. The tender offer and merger are expected to close by the end of May 2026, subject to satisfaction of customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Urgently on the transaction.
Client Highlights

4.17.25

Wilson Sonsini Advises Crux on $50 Million Series B
On April 16, 2025, Crux, a capital markets technology company for the clean economy, announced that it has raised $50 million in Series B funding led by Lowercarbon Capital. Existing investors Andreessen Horowitz (a16z), Ardent Venture Partners, CIV, New System Ventures, and The Three Cairns Group participated in the round. These investors are joined by new investors Liberty Mutual Strategic Ventures, MassMutual Ventures, and OMERS Ventures. Venture capital firms Acrew Capital and Giant Ventures also joined the round. Wilson Sonsini Goodrich & Rosati advised Crux on the transaction.

The Series B round brings Crux’s total funding to over $77 million and will help drive its next phase of growth. The company plans to use the new capital to meet its mission of supporting developers, manufacturers, investors, and lenders through all stages of capital formation. This funding round comes on the heels of Crux’s latest platform innovation: its debt capital marketplace which opens access to a range of debt products alongside Crux’s powerful transferable tax credit marketplace.

The Wilson Sonsini team that advised Crux on the transaction includes:
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.